STOCK TITAN

AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) will release its second quarter 2023 financial results after market close on August 10, 2023. The company will host a live webcast and conference call at 4:30 p.m. EDT/1:30 p.m. PDT to discuss the results and provide a business update.
Positive
  • None.
Negative
  • None.

HAYWARD, Calif., July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2023 financial results after market close on Thursday, August 10, 2023, then host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the results and provide an update on the Company's business.  

Webcast Information

The webcast can be accessed here or by visiting the Investors section of the Company's website at www.acelrx.com and clicking on the webcast link within News & Events/Upcoming Events section.  The webcast will include a slide presentation and a replay will be available on the AcelRx website for 90 days following the event.

Conference Call Information

Investors who wish to participate in the conference call may do so by dialing 1-866-361-2335 for domestic callers, 1-855-669-9657 for Canadian callers, or 1-412-902-4204 (toll applies) for international callers. The conference ID is 10181172.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. AcelRx is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, with an expected NDA filing in 2023, and PFS-02, a pre-filled phenylephrine syringe with an expected NDA filing in 2024. This release is intended for investors only. For additional information about AcelRx, please visit www.acelrx.com.

AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-second-quarter-2023-financial-results-call-and-webcast-on-august-10-2023-301887209.html

SOURCE AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals will release its second quarter 2023 financial results after market close on Thursday, August 10, 2023.

AcelRx Pharmaceuticals will discuss the second quarter 2023 financial results and provide an update on the company's business.

The webcast can be accessed on the AcelRx Pharmaceuticals website at www.acelrx.com by clicking on the webcast link within the News & Events/Upcoming Events section.

Yes, a replay of the webcast will be available on the AcelRx Pharmaceuticals website for 90 days following the event.

To participate in the conference call, dial 1-866-361-2335 for domestic callers, 1-855-669-9657 for Canadian callers, or 1-412-902-4204 (toll applies) for international callers. The conference ID is 10181172.
Acelrx Pharmaceuticals Inc

NASDAQ:ACRX

ACRX Rankings

ACRX Latest News

ACRX Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Redwood City

About ACRX

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v